\n<div style=”text-align: justify; line-height: 1.7; hyphens: auto;”><\/p>\n
Diagnostic imaging is, historically, the bottleneck of cancer screening. Radiologist fatigue, the massive volume of studies, and the subtlety of incipient lesions contribute to a false-negative rate that modern medicine seeks to eradicate.<\/p>\n
One of the most recent bibliographic pillars is the MASAI study (Mammography Screening with Artificial Intelligence), published in The Lancet Oncology in 2023. This randomized clinical trial, conducted in Sweden with more than 80,000 women, marked a milestone by demonstrating that AI-assisted screening detected 20% more cancers than the conventional double reading performed by two radiologists.<\/p>\n
The most relevant thing was not only the effectiveness of the diagnosisca, but operational efficiency by reducing radiologists’ reading workload by 44%. This suggests that AI does not come to replace the doctor, but to act as a high-precision filter that allows the specialist to focus on complex cases.<\/p>\n
![\"\"](\"https:\/\/invitronews.com\/wp-content\/uploads\/2026\/01\/IN_VITRO_CANCER-IA_1-270x300.png\")
<\/div><\/p>\nAnother advance that has been obtained is the support of the technology behind these advances are the Convolutional Neural Networks (CNN). Unlike traditional algorithms, CNNs \u201clearn\u201d to identify spatial features in images using layers of abstraction.<\/p>\n
In cancer of pulmon, the use of AI in low-dose computed tomography (LDCT) scans has demonstrated superior ability to classify pulmonary nodules. Studies published in 2022 and 2024 indicate that AI models can identify texture and border patterns that are invisible to the human eye, correlating them with genetic biomarkers of malignancy without the need for an immediate invasive biopsy<\/p>\n
.a Digital and the End of Subjectivity<\/strong><\/span><\/p>\n Pathology has long been the \u201cgold standard\u201d of diagnosis, but it is not without inter-observer variability. The transition to Whole Slide Imaging (WSI) has allowed AI to analyze tissue samples at a gigapixel scale. Some utilities that were observed in the2024 in prostate and breast cancer are algorithms trained with millions of biopsy images that can grade tumors (such as the Gleason Score) with an accuracy that matches or exceeds expert pathologists. A key study by Cui et al. (2024) highlights how AI can identify microscopic foci of lymph node metastases that are often overlooked in manual analysis, enabling a stage of mucho more accurate.<\/p>\n This advance allows “precision medicine” because if the AI detects a specific morphological signature associated with a genetic mutation (such as HER2 in breast canceraMA), treatment can be customized from day one, avoiding ineffective and toxic therapies.<\/p>\n Liquid Biopsies and Multicancer Diagnosis (MCED)<\/strong><\/span><\/p>\n Perhaps the most disruptive area in the last five years is the use of AI to analyze circulating tumor DNA (ctDNA) and other biomarkers in blood.as a Multiple Cancer Early Detection Test (MCED).<\/p>\n The PATHFINDER Study and the Galleri Test<\/strong><\/span><\/p>\n In 2021 and with updates towards 2024, the Galleri<\/strong> test, analysed in the PATHFINDER<\/em> study, showed that it is possible to detectmore than 50 types of cancer through a single blood draw. AI here is indispensable for processing DNA methylation patterns. Since early-stage ctDNA is extremely scarce, algorithms must differentiate between signals from an actual tumor and benign mutations associated with aging (clonal hematopoiesis of undetermined potential). The success of these tests, validated in publications of the Annals of Oncology<\/em> (2021-2022), lies in the fact that AI not only detects if<\/em> there is cancer, but also predicts the organ of origin with 90% accuracy, which drastically accelerates the diagnostic pathway.<\/p>\n Critical Challenges: Data Ethics and Bias<\/strong><\/span> It’s not all technological optimism. The development of AI in oncology faces ethical and technical challenges that must be addressed to ensure equity in health.<\/p>\n 1. Training Bias:<\/strong> If an algorithm is mostly trained with data from patients of European ancestry, itsaccuracy in Latino, African, or Asian populations may decrease dramatically. Current literature (2022-2025) insists on the need for federated and diverse databases.<\/p>\n 2. The \u201cBlack Box\u201d:<\/strong> The difficulty of explaining how<\/em> AI came to a clinical conclusiona remains a barrier to regulatory acceptance. The rise of Explainable AI (XAI)<\/strong> seeks that algorithms visually point out the regions of interest that justify their diagnosis.<\/p>\n 3. False Positives and Overdiagnosis:<\/strong> There is a risk of detecting Indo lesionslenses that would never have caused harm, subjecting patients to unnecessary treatments. The AI of the future must be able to distinguish between \u201caggressive cancer\u201d and \u201cincidental findings.\u201d<\/p>\n Real-World Implementation: 2026 Perspective<\/strong><\/span><\/p>\n In 2026, AI is being integrated directly into hospital information systems (HIS). It is no longer an external tool, but a component of the workflow where the algorithm pre-classifies cases, sending the most urgent ones to the top of the list dthe specialist. Integrating omics data (genomics, proteomics) with clinical and imaging data (radiomics) is the ultimate goal. This holistic view, processed by foundational AI models (similar to large language models, but applied to biology), promises detection so early that cancer could be treated before it is anatomically visible. <\/p>\n <\/strong><\/span>1. L\u00e5ng, K., et al. (2023).<\/strong> Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomized controlled trial.<\/em> The Lancet Oncology<\/strong>. DOI: 10.1016\/S1470-2045(23)00304-2.![\"\"](\"https:\/\/invitronews.com\/wp-content\/uploads\/2026\/01\/IN_VITRO_CANCER-IA_2-e1769697703264-455x300.png\")
<\/div>\n
\n<div style="text-align: justify; line-height: 1.7; hyphens:auto;"><\/p>\n
\n<div style=”text-align: justify; line-height: 1.7; hyphens: auto;”><\/p>\n
\n2. Bera, K., et al. (2022).<\/strong> AI in medical imaging: A review of current state and future perspectives.<\/em> Nstop Reviews Clinical Oncology<\/strong>. A critical review on the clinical validation of algorithms in radiology.
\n3. Klein, E. A., et al. (2021).<\/strong> Clinical validation of a cell-free DNA-based multi-cancer early detection test.<\/em> Annals of Oncology<\/strong>. The base study for the validation of liquid biopsies using machine learning.
\n4. Cui, C., et al. (2024).<\/strong> Deep learning for digital pathology: A review on the current state and future perspectives.<\/em> Journal of Pathology Informatics<\/strong>. Analysis on the automation of tumor grading.
\n5. Schork, N. J. (2024).<\/strong> Artificial Intelligence and Personalized Oncology.<\/em> Cancer Discovery<\/strong>. An analysis of how AI integrates multi-omics data for individualized treatment.
\n6. Arvaniti, E., etal. (2021).<\/strong> Automated Gleason grading of prostate cancer tissue microarrays via deep learning.<\/em> Scientific Reports (Nature)<\/strong>. Validation of AI consistency against human variability.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"